002653 海思科
已收盘 08-14 15:00:00
资讯
新帖
简况
59股获券商买入评级,贵州茅台目标涨幅达83.09%
格隆汇 · 00:39
59股获券商买入评级,贵州茅台目标涨幅达83.09%
海思科涨5.78%,西南证券一周前给出“买入”评级
证券之星 · 08-13 08:22
海思科涨5.78%,西南证券一周前给出“买入”评级
异动快报:海思科(002653)8月13日11点21分触及涨停板
证券之星 · 08-13 03:25
异动快报:海思科(002653)8月13日11点21分触及涨停板
海思科(002653.SZ)获得创新药HSK47977片药物临床试验批准
智通财经 · 08-12 07:47
海思科(002653.SZ)获得创新药HSK47977片药物临床试验批准
海思科公布国际专利申请:“一种双环衍生物PARP抑制剂的晶型及其制备方法和应用”
证券之星 · 08-08
海思科公布国际专利申请:“一种双环衍生物PARP抑制剂的晶型及其制备方法和应用”
8月8日海思科涨5.07%,工银前沿医疗股票A基金重仓该股
证券之星 · 08-08
8月8日海思科涨5.07%,工银前沿医疗股票A基金重仓该股
海思科涨5.07%,西南证券一周前给出“买入”评级
证券之星 · 08-08
海思科涨5.07%,西南证券一周前给出“买入”评级
海思科最新公告:收到创新药HSK47388片临床试验批准通知书
证券之星 · 08-07
海思科最新公告:收到创新药HSK47388片临床试验批准通知书
海思科最新公告:创新药HSK3486获FDA上市许可申请受理
证券之星 · 07-31
海思科最新公告:创新药HSK3486获FDA上市许可申请受理
7月31日海思科涨7.08%,工银前沿医疗股票A基金重仓该股
证券之星 · 07-31
7月31日海思科涨7.08%,工银前沿医疗股票A基金重仓该股
海思科公布国际专利申请:“靶向整合素受体的偶联药物及其应用”
证券之星 · 07-28
海思科公布国际专利申请:“靶向整合素受体的偶联药物及其应用”
异动快报:海思科(002653)7月28日9点41分触及涨停板
证券之星 · 07-28
异动快报:海思科(002653)7月28日9点41分触及涨停板
海思科最新公告:控股股东之一致行动人申萍拟减持不超过1037.34万股
证券之星 · 07-25
海思科最新公告:控股股东之一致行动人申萍拟减持不超过1037.34万股
海思科公布国际专利申请:“一种稠合三环γ-氨基酸衍生物在治疗中枢神经病理性疼痛中的用途”
证券之星 · 07-18
海思科公布国际专利申请:“一种稠合三环γ-氨基酸衍生物在治疗中枢神经病理性疼痛中的用途”
13.65亿定增获受理!海思科解转型资金之渴?
IPO日报国际金... · 07-17
13.65亿定增获受理!海思科解转型资金之渴?
海思科(002653.SZ):创新药HSK47388片获得FDA同意开展临床试验
智通财经 · 07-15
海思科(002653.SZ):创新药HSK47388片获得FDA同意开展临床试验
异动快报:海思科(002653)7月10日10点0分触及涨停板
证券之星 · 07-10
异动快报:海思科(002653)7月10日10点0分触及涨停板
西藏板块盘中拉升,海思科涨7.09%
市场透视 · 07-10
西藏板块盘中拉升,海思科涨7.09%
【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。
金融界 · 07-10
【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。
海思科法定代表人变更为严庞科
金融界 · 07-10
海思科法定代表人变更为严庞科
加载更多
公司概况
公司名称:
海思科医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-01-17
主营业务:
海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是创新药环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。在2022-2023年中国医药行业最具影响力榜单评选中,海思科荣膺四项殊荣,包括医药商业百强企业、医药制造业百强企业、自主创新先锋企业、守法诚信企业。2024年中国医药研发产品线荣获“最佳工业企业”奖项。
发行价格:
20.00
{"stockData":{"symbol":"002653","market":"SZ","secType":"STK","nameCN":"海思科","latestPrice":59.52,"timestamp":1755154980000,"preClose":60.24,"halted":0,"volume":6386049,"delay":0,"changeRate":-0.012,"floatShares":534999999,"shares":1120000000,"eps":0.3127,"marketStatus":"已收盘","change":-0.72,"latestTime":"08-14 15:00:00","open":60.09,"high":60.96,"low":59,"amount":383000000,"amplitude":0.0325,"askPrice":59.52,"askSize":67,"bidPrice":59.51,"bidSize":5,"shortable":0,"etf":0,"ttmEps":0.3127,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1755221400000},"marketStatusCode":5,"adr":0,"adjPreClose":60.24,"symbolType":"stock","openAndCloseTimeList":[[1755135000000,1755142200000],[1755147600000,1755154800000]],"highLimit":66.26,"lowLimit":54.22,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1119917970,"isCdr":false,"pbRate":16.39,"roa":"--","peRate":190.342181,"roe":"1.13%","epsLYR":0.35,"committee":0.328125,"marketValue":66658000000,"turnoverRate":0.0119,"status":1,"floatMarketCap":31871000000},"requestUrl":"/m/hq/s/002653","defaultTab":"news","newsList":[{"id":"2559980249","title":"59股获券商买入评级,贵州茅台目标涨幅达83.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559980249","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559980249?lang=zh_cn&edition=full","pubTime":"2025-08-14 08:39","pubTimestamp":1755131944,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0650527681.SGD","LU0370786039.SGD","LU1960683339.HKD","LU1734074674.USD","83189","BK0028","LU0405327494.USD","BK1610","LU1008478684.HKD","002938","LU1580142542.USD","LU1064131003.USD","LU0577902454.USD","002653","LU0320764599.SGD","BK0175","600519","LU1807302812.USD","LU0048580855.USD","LU0405327148.USD","LU0072913022.USD","LU2097828474.EUR","SG9999000459.SGD","LU0359201612.USD","SG9999014674.SGD","LU0051755006.USD","LU1720050803.USD","LU0039217434.USD","03189","LU2328871848.SGD","LU0588546209.SGD","688099","LU0516422366.SGD","LU0918141887.USD","LU1655091616.SGD","LU0605514214.HKD","LU1997244956.HKD","BK0044","LU0594300179.USD","LU0307460666.USD","LU0326950275.SGD","LU1105468828.SGD","LU0823426308.USD","IE00BMCWC346.EUR","BK0077","159582","LU1439103000.SGD","LU0516422952.EUR","BK0214","600096"],"gpt_icon":0},{"id":"2559450670","title":"海思科涨5.78%,西南证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2559450670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559450670?lang=zh_cn&edition=full","pubTime":"2025-08-13 16:22","pubTimestamp":1755073355,"startTime":"0","endTime":"0","summary":"今日海思科涨5.78%,收盘报60.24元。2025年7月31日,西南证券研究员杜向阳,陈辰发布了对海思科的研报《启动HSK21542注射液用于骨科手术后镇痛的III期临床试验》,该研报对海思科给出“买入”评级。研报中预计公司2025-2027年归母净利润为5.2亿元、6.8亿元和8.9亿元,对应PE分别为104倍、79倍和61倍,维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为57.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081300025670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","002653"],"gpt_icon":0},{"id":"2559267639","title":"异动快报:海思科(002653)8月13日11点21分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2559267639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559267639?lang=zh_cn&edition=full","pubTime":"2025-08-13 11:25","pubTimestamp":1755055524,"startTime":"0","endTime":"0","summary":"证券之星8月13日盘中消息,11点21分海思科触及涨停板。目前价格62.65,上涨10.01%。其所属行业化学制药目前上涨。领涨股为首药控股。该股为创新药,健康中国,医药概念热股,当日创新药概念上涨1.91%,健康中国概念上涨1.18%,医药概念上涨0.98%。8月12日的资金流向数据方面,主力资金净流出715.46万元,占总成交额3.5%,游资资金净流出2734.01万元,占总成交额13.37%,散户资金净流入3449.47万元,占总成交额16.86%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081300014409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0033","BK0188","BK0028","002653","BK0239"],"gpt_icon":0},{"id":"2558147246","title":"海思科(002653.SZ)获得创新药HSK47977片药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2558147246","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558147246?lang=zh_cn&edition=full","pubTime":"2025-08-12 15:47","pubTimestamp":1754984833,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)发布公告,公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》,涉及药品:“HSK47977”。HSK47977是公司自主研发的一种口服BCL6(人B细胞淋巴瘤因子6)PROTAC小分子制剂,可以靶向结合和降解BCL6蛋白,进而抑制肿瘤细胞的发生和发展,拟用于非霍奇金淋巴瘤的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1328485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0188","159992","BK1574","BK0033","002653","BK0077","06978","BK0028","BK0239"],"gpt_icon":0},{"id":"2558572022","title":"海思科公布国际专利申请:“一种双环衍生物PARP抑制剂的晶型及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2558572022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558572022?lang=zh_cn&edition=full","pubTime":"2025-08-09 05:06","pubTimestamp":1754687176,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示海思科(002653)公布了一项国际专利申请,专利名为“一种双环衍生物PARP抑制剂的晶型及其制备方法和应用”,专利申请号为PCT/CN2025/075378,国际公布日为2025年8月7日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来海思科已公布的国际专利申请22个。结合公司2024年年报财务数据,2024年公司在研发方面投入了6.24亿元,同比增20.8%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080900004357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0033","002653","BK0188","BK0239","BK0077"],"gpt_icon":0},{"id":"2557549009","title":"8月8日海思科涨5.07%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2557549009","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557549009?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:16","pubTimestamp":1754640963,"startTime":"0","endTime":"0","summary":"证券之星消息,8月8日海思科涨5.07%创60日新高,收盘报59.46元,换手率0.76%,成交量4.08万手,成交额2.35亿元。重仓海思科的前十大公募基金请见下表:该股最近90天内共有5家机构给出评级,买入评级5家;过去90天内机构目标均价为50.02。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共38家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800025060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0077","BK0188","BK0033","BK0239","BK0028","002653"],"gpt_icon":0},{"id":"2557541837","title":"海思科涨5.07%,西南证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2557541837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557541837?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:15","pubTimestamp":1754640948,"startTime":"0","endTime":"0","summary":"今日海思科涨5.07%,收盘报59.46元。2025年7月31日,西南证券研究员杜向阳,陈辰发布了对海思科的研报《启动HSK21542注射液用于骨科手术后镇痛的III期临床试验》,该研报对海思科给出“买入”评级。研报中预计公司2025-2027年归母净利润为5.2亿元、6.8亿元和8.9亿元,对应PE分别为104倍、79倍和61倍,维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为57.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800025056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","002653"],"gpt_icon":0},{"id":"2557155622","title":"海思科最新公告:收到创新药HSK47388片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2557155622","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557155622?lang=zh_cn&edition=full","pubTime":"2025-08-07 18:11","pubTimestamp":1754561473,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称,公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》,同意HSK47388片开展临床试验。该药品是公司自主研发的口服、强效、高选择性的药物,拟用于自身免疫疾病的治疗,属于化学药品1类。临床前研究显示,HSK47388具有良好的耐受性和较大的安全窗。但创新药研发周期长、风险高,存在不确定性,投资者需谨慎决策。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080700031763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0033","06978","BK0077","002653","BK1161","BK0028","BK0239","159992","BK0188"],"gpt_icon":0},{"id":"2555889589","title":"海思科最新公告:创新药HSK3486获FDA上市许可申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2555889589","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555889589?lang=zh_cn&edition=full","pubTime":"2025-07-31 18:21","pubTimestamp":1753957289,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称,公司于7月30日收到美国食品药品监督管理局(FDA)下发的受理通知,HSK3486(环泊酚注射液)新药上市申请(NDA)符合药品注册的有关要求,决定予以受理。HSK3486是公司自主研发的1类静脉麻醉药物,于2020年12月国内获批上市。FDA本次受理是海思科创新药研发迈向国际的关键一步,若成功上市,将为全球患者带来更安全、更高效的麻醉镇静新选择。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073100031053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","06978","BK0188","BK1574","BK0033","BK1161","159992","002653","BK0077"],"gpt_icon":0},{"id":"2555073740","title":"7月31日海思科涨7.08%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2555073740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555073740?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:17","pubTimestamp":1753949869,"startTime":"0","endTime":"0","summary":"证券之星消息,7月31日海思科涨7.08%创60日新高,收盘报55.79元,换手率1.27%,成交量6.8万手,成交额3.72亿元。重仓海思科的前十大公募基金请见下表:该股最近90天内共有6家机构给出评级,买入评级6家;过去90天内机构目标均价为50.02。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共38家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。该公募基金现任基金经理为赵蓓。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073100025258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0033","002653","BK0028","BK0239","159891"],"gpt_icon":0},{"id":"2555670124","title":"海思科公布国际专利申请:“靶向整合素受体的偶联药物及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2555670124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555670124?lang=zh_cn&edition=full","pubTime":"2025-07-29 04:55","pubTimestamp":1753736119,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示海思科(002653)公布了一项国际专利申请,专利名为“靶向整合素受体的偶联药物及其应用”,专利申请号为PCT/CN2025/072803,国际公布日为2025年7月24日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来海思科已公布的国际专利申请20个。结合公司2024年年报财务数据,2024年公司在研发方面投入了6.24亿元,同比增20.8%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900005120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002653","BK0077","BK0188","BK0239","BK0033"],"gpt_icon":0},{"id":"2554744372","title":"异动快报:海思科(002653)7月28日9点41分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2554744372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554744372?lang=zh_cn&edition=full","pubTime":"2025-07-28 09:45","pubTimestamp":1753667130,"startTime":"0","endTime":"0","summary":"证券之星7月28日盘中消息,9点41分海思科触及涨停板。目前价格53.02,上涨10.0%。其所属行业化学制药目前上涨。领涨股为尔康制药。该股为幽门螺杆菌概念,医药,创新药概念热股,当日幽门螺杆菌概念概念上涨1.28%,医药概念上涨0.72%,创新药概念上涨0.61%。7月25日的资金流向数据方面,主力资金净流出1010.66万元,占总成交额7.93%,游资资金净流入1449.58万元,占总成交额11.37%,散户资金净流出438.92万元,占总成交额3.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072800004568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002653","BK0028","BK0077","BK0239","BK0033"],"gpt_icon":0},{"id":"2554634769","title":"海思科最新公告:控股股东之一致行动人申萍拟减持不超过1037.34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2554634769","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554634769?lang=zh_cn&edition=full","pubTime":"2025-07-25 18:41","pubTimestamp":1753440084,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称,公司控股股东之一致行动人申萍计划自公告披露之日起十五个交易日后的三个月内,通过大宗交易或集中竞价方式减持公司股份合计不超过1037.34万股,减持比例合计不超过公司总股本的0.926%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500032392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0028","BK0239","BK0077","BK0188","002653"],"gpt_icon":0},{"id":"2552149016","title":"海思科公布国际专利申请:“一种稠合三环γ-氨基酸衍生物在治疗中枢神经病理性疼痛中的用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2552149016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552149016?lang=zh_cn&edition=full","pubTime":"2025-07-19 04:52","pubTimestamp":1752871939,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示海思科(002653)公布了一项国际专利申请,专利名为“一种稠合三环γ-氨基酸衍生物在治疗中枢神经病理性疼痛中的用途”,专利申请号为PCT/CN2025/070898,国际公布日为2025年7月17日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来海思科已公布的国际专利申请18个。结合公司2024年年报财务数据,2024年公司在研发方面投入了6.24亿元,同比增20.8%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071900003368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0188","BK0239","BK0028","BK0077","002653"],"gpt_icon":0},{"id":"2552047172","title":"13.65亿定增获受理!海思科解转型资金之渴?","url":"https://stock-news.laohu8.com/highlight/detail?id=2552047172","media":"IPO日报国际金...","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552047172?lang=zh_cn&edition=full","pubTime":"2025-07-17 08:30","pubTimestamp":1752712200,"startTime":"0","endTime":"0","summary":"近年来,受仿制药集采影响,海思科正经历从过往专注于“创新仿制药”研发,向“仿创结合”的研发生态的快速转型。根据公司2024年年报,海思科实现营业收入37.21亿元,同比增长10.92%;净利润3.96亿元,同比增长34%。值得一提的是,在年报发布当日,公司股价实现涨停,市值首次超过500亿元,创下历史新高,资本热捧的背后,或反映了市场对海思科创新药转型战略的认可。海思科指出,上述项目均已取得阶段性的研究成果,为本项目实施奠定了基础。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2025-07-17/doc-inffttzw0336129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0239","BK0033","BK0077","002653","BK0188"],"gpt_icon":0},{"id":"2551157660","title":"海思科(002653.SZ):创新药HSK47388片获得FDA同意开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2551157660","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551157660?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:46","pubTimestamp":1752569200,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)披露近日收到美国食品药品监督管理局(“FDA”)的 Study May Proceed Letter,根据FDA相关规定,经审查,公司2025年5月递交的HSK47388片临床试验申请符合药品注册的有关要求,同意本品开展临床试验。公告称,HSK47388片是公司自主研发的口服、强效、高选择性的药物,拟用于自身免疫疾病的治疗。临床前研究结果显示,HSK47388可以剂量依赖地抑制大鼠炎症反应,同时也表现出了良好的耐受性和较大的安全窗,是一款极具开发潜力的药物,有望为自身免疫疾病患者提供一种新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","06978","03347","BK1574","BK0033","BK0028","002653","BK0239","BK1141","BK1161","BK0188","BK1583","BK1576","159992"],"gpt_icon":0},{"id":"2550693380","title":"异动快报:海思科(002653)7月10日10点0分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2550693380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550693380?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:05","pubTimestamp":1752113124,"startTime":"0","endTime":"0","summary":"证券之星7月10日盘中消息,10点0分海思科触及涨停板。目前价格46.41,上涨10.0%。其所属行业化学制药目前上涨。领涨股为联环药业。该股为西藏概念,创新药,幽门螺杆菌概念概念热股,当日西藏概念概念上涨1.55%,创新药概念上涨0.97%,幽门螺杆菌概念概念上涨0.88%。7月9日的资金流向数据方面,主力资金净流出654.58万元,占总成交额4.94%,游资资金净流出370.96万元,占总成交额2.8%,散户资金净流入1025.55万元,占总成交额7.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000009397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002653","BK0028","BK0077","BK0188","BK0033"],"gpt_icon":0},{"id":"2550985456","title":"西藏板块盘中拉升,海思科涨7.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550985456","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550985456?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:48","pubTimestamp":1752112094,"startTime":"0","endTime":"0","summary":"07月10日,西藏板块盘中拉升,截至09点48分,西藏板块整体指数上涨1.07%,报2193.190点。从个股上来看,该板块的成分股中,海思科涨7.09%,多瑞医药、华钰矿业2只股涨幅超过5%。从资金上来看,截止发稿,西藏板块主力净流入为8881.17万,其中华钰矿业受到资金热捧,主力净流入8301.42万;拉长时间线来看,该板块近20日主力资金净流入-21.92亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710094814a6a0761b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710094814a6a0761b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","002653","BK0242","601020","BK0077","BK0188","BK0182","BK0239","BK0033"],"gpt_icon":0},{"id":"2550660707","title":"【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550660707","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550660707?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:46","pubTimestamp":1752111976,"startTime":"0","endTime":"0","summary":"创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f4ae4484572f275cf3aa38bb605c2821","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/10094651600059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0033","603590","159992","BK0250","BK0188","BK0077","688799","BK0028","603716","BK0229","BK1574","BK0239","002653","06978","688321","BK1161","603086"],"gpt_icon":0},{"id":"2550030664","title":"海思科法定代表人变更为严庞科","url":"https://stock-news.laohu8.com/highlight/detail?id=2550030664","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550030664?lang=zh_cn&edition=full","pubTime":"2025-07-10 08:17","pubTimestamp":1752106669,"startTime":"0","endTime":"0","summary":"近日,天眼查APP显示,海思科医药集团股份有限公司(简称“海思科”)法定代表人发生变更,从范秀莲变为严庞科。资料显示,海思科医药集团股份有限公司法定代表人为严庞科,成立于2005年,位于山南市,是一家以从事医药制造业为主的企业。企业注册资本111991.797万人民币,实缴资本111991.797万人民币。通过天眼查大数据分析,海思科医药集团股份有限公司共对外投资了20家企业,参与招投标项目31次,知识产权方面有商标信息468条,专利信息65条,此外企业还拥有行政许可14个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10081751597787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0188","002653","BK0033","BK0077","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1755206589203,"stockEarnings":[{"period":"1week","weight":0.0518},{"period":"1month","weight":0.28},{"period":"3month","weight":0.4078},{"period":"6month","weight":0.9798},{"period":"1year","weight":1.1596},{"period":"ytd","weight":0.8035}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.0461},{"period":"3month","weight":0.0888},{"period":"6month","weight":0.0955},{"period":"1year","weight":0.2862},{"period":"ytd","weight":0.0939}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海思科医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9072人(较上一季度减少27.81%)","perCapita":"59023股","listingDate":"2012-01-17","address":"西藏自治区山南市乃东区泽当镇三湘大道17号","registeredCapital":"111991万元","survey":" 海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是创新药环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。在2022-2023年中国医药行业最具影响力榜单评选中,海思科荣膺四项殊荣,包括医药商业百强企业、医药制造业百强企业、自主创新先锋企业、守法诚信企业。2024年中国医药研发产品线荣获“最佳工业企业”奖项。","listedPrice":20},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海思科,002653,海思科股票,海思科股票老虎,海思科股票老虎国际,海思科行情,海思科股票行情,海思科股价,海思科股市,海思科股票价格,海思科股票交易,海思科股票购买,海思科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}